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ABSTRACT
Renal calcification (RCALC) resulting in nephrolithiasis and nephrocalcinosis, which affects10% of adults by 70 years of age, involves
environmental and genetic etiologies. Thus, nephrolithiasis and nephrocalcinosis occurs as an inherited disorder in65% of patients,
andmay be associated with endocrine and metabolic disorders including: primary hyperparathyroidism, hypercalciuria, renal tubular
acidosis, cystinuria, and hyperoxaluria. Investigations of families with nephrolithiasis and nephrocalcinosis have identified some
causative genes, but further progress is limited as large families are unavailable for genetic studies. We therefore embarked on
establishing mouse models for hereditary nephrolithiasis and nephrocalcinosis by performing abdominal X-rays to identify renal
opacities in N-ethyl-N-nitrosourea (ENU)-mutagenized mice. This identified a mouse with RCALC inherited as an autosomal dominant
trait, designatedRCALC type2 (RCALC2). Genomewidemapping located theRcalc2 locus toa16-Mbp regiononchromosome11D-E2
and whole-exome sequence analysis identified a heterozygous mutation in the DNA polymerase gamma-2, accessory subunit (Polg2)
resulting in a nonsense mutation, Tyr265Stop (Y265X), which co-segregated with RCALC2. Kidneys of mutant mice (Polg2+/Y265X) had
lower POLG2 mRNA and protein expression, compared to wild-type littermates (Polg2+/+). The Polg2+/Y265X and Polg2+/+ mice had
similar plasma concentrations of sodium, potassium, calcium, phosphate, chloride, urea, creatinine, glucose, and alkaline phosphatase
activity; and similar urinary fractional excretion of calcium, phosphate, oxalate, and protein. Polg2 encodes the minor subunit of the
mitochondrial DNA (mtDNA) polymerase and themtDNA content in Polg2+/Y265X kidneys was reduced compared to Polg2+/+mice, and
cDNAexpressionprofiling revealed differential expressionof 26genes involved in several biological processes includingmitochondrial
DNA function, apoptosis, and ubiquitination, the complement pathway, and inflammatory pathways. In addition, plasma of
Polg2+/Y265X mice, compared to Polg2+/+ littermates had higher levels of reactive oxygen species. Thus, our studies have identified a
mutant mousemodel for inherited renal calcification associated with a Polg2 nonsensemutation. © 2018 The Authors. Journal of Bone
and Mineral Research Published by Wiley Periodicals, Inc.
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Introduction
Renal calcification, which comprises nephrocalcinosis andnephrolithiasis (kidney stones), has a multifactorial etiol-
ogy involving environmental and genetic determinants.(1)
Nephrocalcinosis and nephrolithiasis, which are calcification of
the renal parenchyma and collecting system, respectively,
affect up to 10% of the adult population by the age of
70 years.(1–3) Over 80% of kidney stones are composed of
calcium complexed with oxalate or apatite, which form when
urine becomes supersaturated with salts such as calcium
oxalate or calcium phosphate or when concentrations of stone
inhibitors such as citrate, uromodulin, and osteopontin are
reduced.(1,4,5) Nephrolithiasis and nephrocalcinosis are often
associated with endocrine and metabolic disorders including:
primary hyperparathyroidism, hypercalciuria, renal tubular
acidosis, cystinuria, low urinary volume, and hyperoxaluria.(2,4)
However, 30% of individuals with kidney stones have no
obvious metabolic defect and these patients are designated as
having idiopathic nephrolithiasis.(2,4,6,7)
Evidence for a genetic contribution to these renal calcifica-
tion disorders has been provided by family and twin studies.
Thus, up to 65% of kidney stone patients have an affected
family member(8,9) and twin studies have estimated the
heritability of hypercalciuria(10) and kidney stones(11) to be
52% and 56%, respectively. Studies of families with rare
monogenic disorders associated with hypercalciuric nephroli-
thiasis and/or nephrocalcinosis, such as Bartter syndrome, Dent
disease, autosomal dominant hypocalcaemia, and distal renal
tubular acidosis have identified mutations in >30 genes
involved in calcium transport regulation (Supporting Table
1).(3,12,13) Furthermore, genomewide association studies and
targeted sequencing of genes with known roles in calcium and
vitamin D metabolism have identified associations between
nephrolithiasis and common sequence variants in >10
additional genes (Supporting Table 1).(1,14–16) However, these
account for only 15% to 20% of cases,(3,12) and the
identification of further monogenic causes of nephrolithiasis
are limited by the unavailability of large families. To overcome
these difficulties and facilitate the identification of genetic
abnormalities causing idiopathic nephrolithiasis and nephro-
calcinosis, we embarked on establishing mouse models for
renal calcification by investigating the phenotypes of progeny
of mice treated with the chemical mutagen N-ethyl-N-nitro-
sourea (ENU). ENU is an alkylating agent that primarily
introduces point mutations via transfer of the ENU alkyl
group to the DNA base followed by mispairing and subsequent
base-pair substitution during the next round of DNA replica-
tion.(17,18) In phenotype-driven screens, offspring of mutagen-
ized mice are assessed for abnormalities in a hypothesis-
generating strategy, which may elucidate new genes, path-
ways, and mechanisms for disease phenotypes.(17,18) ENU
mutagenesis has generated a variety of mouse models for
metabolic and renal disorders including a mouse model for
renal failure due to a substitution in aquaporin-11,(19) and a
mouse model for idiopathic hypercalciuria.(20) Here, we report
an ENU-induced mouse model of renal calcification (RCALC),
that is referred to as RCALC type 2 (RCALC2), and is associated
with a Tyr265Stop (Y265X) nonsense mutation in the DNA
polymerase subunit gamma-2, accessory protein (Polg2), which
functions in the replication of mitochondrial DNA (mtDNA)-
encoded proteins.
Subjects and Methods
Animals
Animal studies were carried out using guidelines issued by the
UK Medical Research Council in Responsibility in Use of Animals
for Medical Research (July 1993) and UK Home Office project
license numbers (30/2250 and 30/2752). ENU-treated G0 BALB/c
male mice were mated to female C3H/HeH (C3H) mice to
produce first generation (G1) progeny. Male G1 offspring were
X-rayed for renal opacities and sperm archived.(20) Archived
RCALC2 founder male sperm was used for in vitro fertilization
(IVF) of C3H oocytes to derive G2 animals.(20) Mice were fed on a
standard diet (Rat and Mouse number 3; Special Diet Services,
Essex, UK) that contained 1.15% calcium, 0.58% phosphate, and
4089 IU/kg of vitamin D, and provided with water ad libitum.(21)
Metabolic cage studies, plasma and urine biochemistry
Adult (16-week old) G2 mice were individually housed in
metabolic cages (Techniplast, Louviers, France) for 5 days with
free access to food and water.(22) Mice were weighed before and
after the study, and food andwater intakewasmonitored. Twenty-
four-hour urine samples were collected in the presence of sodium
azideandblood sampleswerecollected from lateral tail vein or the
internal jugular vein in lithiumheparin Microvette tubes (Sarstedt,
Leicester, UK) following terminal anesthesia, as described.(22)
Plasma and urine were appropriately analyzed for sodium,
potassium, chloride, total calcium, phosphate, urea, glucose,
creatinine, oxalate, total protein, albumin, and alkaline phospha-
tase activity on a Beckman Coulter AU680 analyzer (Beckman
Coulter, High Wycombe, UK).(21) Plasma calcium was adjusted for
variations in albumin concentrations using the formula: (plasma
calcium (mmol/L)– [(plasma albumin (g/L)– 30) 0.02], as re-
ported.(21) The fractional excretion of calciumandphosphatewere
calculated using the formula Ux/Px
PCr/UCr, where Ux is the urinary
concentration of the filtered substance (substance x) inmmol/L, Px
is the plasma concentration of substance x in mmol/L, UCr is the
urinary concentration of creatinine in mmol/L, and PCr is the
plasma concentration of creatinine in mmol/L.(21) A Kruskal-Wallis
test was undertaken formultiple comparisons, and any significant
differences identified were further assessed using the Dunn’s test
for nonparametric pairwise multiple comparisons. All analyses
were undertaken using Prism software (GraphPad Software, Inc.,
La Jolla, CA, USA), and a value of p< 0.05 was considered
significant for all analyses.
Kidney histology and immunohistochemistry
Kidneys were obtained from adult (16 to 33 weeks old) mice,
halved, fixed in 10% neutral-buffered formalin overnight, and
embedded in paraffin wax. Four-micrometer (4-mm) serial
sections were prepared and stained with either: hematoxylin
and eosin, von Kossa, or Masson’s Trichrome, as described.(20)
Images were collected on a Nikon Eclipse E400 microscope
(Kingston-upon-Thames, UK), equipped with a Nikon DXM1200C
digital camera. Measurements of calcified regions were per-
formed using the Nikon Eclipse E400 software.
Genetic mapping
Genomic DNA was isolated from tail biopsies using the Gentra
PureGene kit (Qiagen, Manchester, UK) and genomewide scans
performed by pyrosequencing(23) using a panel of 59 informa-
tive SNPs distributed across 19 autosomes, at 20-cM to 30-cM
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intervals. Polymorphic positions were analyzed using a PSQ-96
system (Qiagen).(20) Chromosomal linkage was verified by non-
inheritance of BALB/c alleles of SNPs of interest in 13 unaffected
littermates. G2 and G3 mice were genotyped for additional
markers within the critical region.
Exome sequence analysis
Sequencing libraries were constructed using the NimbleGen kit
(Roche, West Sussex, UK) and libraries combined in pools of
six for targeted capture, using the SeqCap EZ Mouse Exome
SR v2.2 (target regions available from ftp://ftp.jax.org/
Genome_Biology_mouse_exomes). Libraries were assessed
precapture and postcapture for quality and yield, using a
High Sensitivity DNA assay (Agilent, Santa Clara, CA, USA) and
Library Quantification Kit (KAPABiosystems, Gillingham, UK).
Massive parallel sequencing was performedwith six samples per
flow cell lane, using the HiSeq2000 platform and SBS reagents
(Illumina, San Diego, CA, USA) to generate 100-bp paired-end
reads. Illumina Data Analysis Pipeline software (CASAVA 1.8.1)
was used for initial base calling and data multiplexing. Illumina
reads were mapped to the mouse genome (mm9) using the
Burrows-Wheeler Aligner (BWA)_v2(24) with the default param-
eters. Single-nucleotide variant (SNV) calls were made using a
customized version of The Genome Analysis Toolkit (GATK)(25)
with default parameters. Several triaging steps were made to
reduce false positives.(26) The 17 Mouse Genome dataset(27) was
used to filter inbred SNP sites from the RCALC2 SNV dataset, and
common sites were removed from further investigation. The
remaining SNVs were further filtered by removing sites with an
allele frequency<35% and>80%, a read depth<3 and a quality
score >200. The final RCALC2 SNV dataset was annotated with
next-generation sequencing (NGS)-SNP.(28)
DNA sequence analysis
Variants were validated in G2 mice by Sanger DNA sequencing,
using appropriate gene-specific primers (Sigma, Gillingham, UK),
followed by dideoxynucleotide sequencing using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Life Technologies,
Carlsbad, CA, USA) and an automated detection system
(ABI3730 capillary sequencer; Applied Biosystems, Carlsbad,
CA, USA).(29) DNA samples from G2 and G3 mice were assessed
by restriction endonuclease analysis using HindIII and BsrDI
restriction endonucleases, as described.(20)
Protein sequence alignment and protein prediction
Protein sequenceswere aligned using ClustalW(30) and the effect
of mutations predicted using MutationTaster (http://www.
mutationtaster.org/).(31)
RNA extractions, cDNA expression profiling, and
quantitative RT-PCR analysis
Total RNA was extracted from kidney samples taken from adult
(30 to 33 weeks old) RCALC2 mice or parental wild-type (WT),
BALB/c, and C3H mice littermates (n¼ 4 to 8 mice per group)
using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Following
DNaseI-treatment, RNA was purified using an RNeasy Mini kit
(Qiagen). Nine-micrograms (9mg) total RNA was used for first-
strand and second-strand cDNA synthesis using the One-Cycle
cDNA Synthesis Kit (Affymetrix, High Wycombe, UK) according
to the manufacturer’s instructions. Biotinylated cRNA was
synthesized using the Genechip IVT Labelling Kit (Affymetrix).
Fifteen-micrograms (15mg) of fragmented cRNA was hybridized
for 16 hours at 45°C to Mouse Genome 430 2.0 arrays
(Affymetrix). Following hybridization the arrays were washed
and stained with streptavidin-phycoerythrin in the Affymetrix
Fluidics Station 450 and scanned using the GeneChip Scanner
3000 7G. The image data were analyzed with GCOS 1.4 using
Affymetrix default analysis settings and global scaling as a
normalization method. The dataset of the arrays were normal-
ized using Robust Multi-chip Average algorithm in respect to the
sequence-specific probe affinities.(32) Differences between the
datasets were investigated using the t statistic. Genes with a
significant p value (p< 0.05), and >1.10-fold difference in
expression (in the same direction) versus both parental strains
were selected for further evaluation. Quantitative RT-PCR (qRT-
PCR) reactions were performed in cDNA prepared from the
kidneys of 4 to 5 Polg2+/+ and 4 Polg2+/Y265X mice using the
QuantiTect SYBR Green Kit (Qiagen) and utilizing a Rotorgene 5
(Qiagen), as described.(33) All qRT-PCR test samples were
normalized to the geometric mean of three housekeeper genes
(cyclin D1 [Ccnd1], cyclin D2 [Ccnd2], and b-actin [Actb]), as
described.(34) Delta threshold cycle (DCt) values were derived by
subtracting the Ct value of the housekeeping gene from the
experimental gene. The average of theDCt values was then used
as a reference to calculate DDCt values. Fold-changes were
calculated using the formula 2–DDCt. For mtDNA quantification,
mt-ND1 levels were normalized to the nuclear gene b-actin
(Actb). Ct values were obtained from the start of the log phase on
Rotorgene Q Series Software and Ct values analyzed in Microsoft
Excel 97–2010 (Microsoft Corp., Redmond, WA, USA) using the
Pfaffl method.(33–35) Statistical analyses were performed using
the Student’s t test.
Analysis of protein expression
Whole-kidney lysates from RCALC2 mutant mice and WT
littermate mice were prepared using NP40 lysis buffer (50mM
Tris-HCl pH7.4, 1mM EDTA, 150mM NaCl, 1% NP40, protease
inhibitors), resuspended in Laemmli buffer, boiled, and separated
by sodium-dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE), as described.(34) Blots were electrotransferred to
polyvinylidene fluoride membranes (Millipore, Abingdon, UK)
and probed with anti-POLG (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-POLG2 (Aviva SystemsBiology, SanDiego,CA,
USA) or anti-alpha-tubulin (Abcam, Cambridge, UK) primary
antibodies, followedbyhorseradishperoxidase (HRP)-conjugated
secondary antibodies (Biorad, Watford, UK). Blots were visualized
on a BioRad Chemidoc XRSþ system and densitometry
performed using ImageJ software (NIH, Bethesda, MD, USA;
https://imagej.nih.gov/ij/).(20,33) For protein detection in urine
1mg/mL samples were resolved on SDS-PAGE gels and stained
with Coomassie blue solution.
Intracellular reactive oxygen species assay
Reactive oxygen species (ROS) generation was assessed using
the OxiSelect Intracellular ROS assay kit (Cell Biolabs, San Diego,
CA, USA), according to the manufacturer’s protocol and
adapting described methods.(36) Plasma samples from four
RCALC2mutant mice and four WT littermates were used for ROS
studies. A standard curve was prepared using the supplied
standards. Fluorescence was determined using a CytoFluor
microplate reader (PerSeptive Biosystems, Framingham, MA,
USA) at 485-nm excitation and 530-nm emission wavelengths,
and relative fluorescence units derived from the standard curve.
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Data was expressed as mean SE compared to that of WT,
which was expressed as 1. Statistical analyses were performed
using two-way ANOVA.
Apoptosis assay
Apoptosiswas assessed inwhole-kidney lysates using theCaspase-
Glo 3/7 luminescence assay (Promega) measuring levels of active-
caspase 3/7, as described.(29) Luminescence was measured using a
Turner Biosystems luminometer (Promega, Southampton, UK).
Experiments were performed in 10 independent kidney samples
each, from RCALC2 mutant mice and WT littermates. Data was
expressed as fold change SE for each group. Statistical analyses
were performed using two-way ANOVA.
Statistical analysis
Statistical analyses were performed using the Kruskal-Wallis test,
Dunn’s test for nonparametric pairwise multiple comparisons,
two-way ANOVA, and the Student’s t test.
Results
Identification and characterization of RCALC2, a mouse
model for renal calcification
The RCALC2 founder was identified from a radiological screen
for renal opacities in 1745 12-month-old male G1 offspring of
ENU-treated BALB/c males and WT C3H/HeH (C3H) females. IVF
was used to derive 85 G2 mice (48 males [M] and 37 females [F]),
using sperm from the RCALC2 founder, and 138 G3 mice (68 M
and 70 F) were derived from matings of G2 mice. Renal
calcification was assessed in adult mice (16 to 33 weeks of age)
by von Kossa staining of kidney sections, to detect calcium
deposits, and hematoxylin and eosin, to detect tissue morphol-
ogy of histological sections (Fig. 1A). Calcification was
predominantly present within the renal papilla and cortex,
and was not associated with fibrosis, which was assessed by
Masson’s Trichrome staining (Supporting Fig. 1A). Regions of
calcification within the renal papilla and cortex were measured
and shown to have a mean diameter of 20.42mm (range, 10.77
Fig. 1. Identification of the Polg2-Y265X mutation in RCALC2 mice. (A) Histological sections of the kidneys of RCALC2 mice and unaffected littermates
stained with: hematoxylin and eosin, to detect tissuemorphology; and von Kossa, to detect calcium deposits. Renal papillary images are displayed at the
top and renal cortex at the bottom for each stain. Gross morphological changes were absent in RCALC2 mouse kidneys. Calcification was predominantly
of papillary origin, but was also located in the kidney cortex of some affected RCALC2 mice. Scale bar¼ 10 mm. (B) Haplotype analysis of 39 G2 RCALC2
mice. Each box represents the genotype for the polymorphic locus. Filled box, BALB/c allele; open box, C3H allele. The number of mice that displayed
each haplotype is indicated below each column. Analysis localized the RCALC2 locus to a16-Mb region between D11Mit132 and D11Mit214, on mouse
chromosome 11. (C) DNA sequence analysis of Polg2 in DNA extracted from an unaffected (WT) and an RCALC2 (mutant) mouse, confirmed the whole-
exome analysis result of a heterozygous C-to-A transversion in codon 265 in RCALC2 mice, that predicted an alteration of the WT tyrosine (Tyr) to a
premature stop codon, and to result in gain of a HindIII restriction enzyme site. (D) HindIII restriction enzyme digestion of PCR products was used to
confirm the presence, or absence, of the Tyr265Stop (Y265X) mutation in mutant RCALC2 G2 mice and WT mice, respectively (n¼ 5 of each shown). The
presence of the HindIII restriction site, results in 2mutant products (bands). RCALC2mice are observed to have 3 bands, comprising aWT band of 359 bp
and 2 mutant bands of 188 bp and 171 bp; thus RCALC2 mice are heterozygous for the WT and mutant alleles. In contrast, the WT mice have only one
band at 359 bp and are therefore homozygous for the WT allele. S¼DNA size marker; WT¼wild-type.
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to 43.21mm) (sections from n¼ 42 mice). The mean area of
calcification was estimated to be 381.09mm2 (range, 10.77 to
43.21mm2). These calcified regions were therefore too small to
extract high-quality material that would allow for chemical
analysis of stone composition. Forty-three (24 M, 19 F) of the 85
G2 mice (50.6% and 60 [33 M, 27 F] of the 138 G3 mice [43.3%])
had renal calcification, yielding affected to nonaffected ratios in
G2 mice¼ 1:0.98 and G3 mice¼ 1:1.3, which were not
significantly different from the 1:1 ratio expected for an
autosomal dominant mode of inheritance with high penetrance
(observed versus expected ratios for G2 mice were 43 affected:
42 unaffected, versus 42.5 affected:42.5 unaffected [x2 test,
p¼ 1]), and for G3micewere 60 affected:78 unaffected versus 69
affected:69 unaffected [x2 test, p¼ 0.28]). In addition, the ratio of
affectedmales (M) to affected females (F) for the G2 and G3mice
was 1.3:1 and 1.2:1, respectively, and consistentwith the 1:1 ratio
expected for an autosomal dominant disorder (observed versus
expected ratios for G2 mice were 24M:19 F versus 21.5 M:21.5 F
[x2 test, p¼ 0.52] and for G3 mice were 33M:27 F versus 30M:30
F [x2 test, p¼ 0.30]). In addition, the ratios of WT (ie, unaffected)
males to females for the G2 and G3 mice were 1.3:1 and 0.8:1,
respectively, and not significantly different from the expected
1:1 ratio for an autosomal dominant trait (observed versus
expected ratios for G2 mice were 24M:18 F versus 21M:21 F [x2
test, p¼ 0.43]), and for G3 mice were 35 M:43 F versus 39 M:39 F
[x2 test, p¼ 0.41]). Furthermore, a backcross of RCALC2 mice
onto the C57BL/6 strain resulted in 43 (27 males and 16 females)
of 65 mice (66.2%) with renal calcification, showing that the
phenotype is unrelated to background strain. Calcification was
absent from heart sections indicating that the observed
calcification is tissue-specific, and not associated with ectopic
calcification in multiple tissues (Supporting Fig. 1B). The RCALC2
mice were not observed to have any other abnormalities.
Mapping of the Rcalc2 locus to chromosome 11D-E2 and
identification of the Polg2 nonsense mutation by whole-
exome sequence analysis
Genomewide mapping using DNA samples from 13 affected
RCALC2 mice (8 males and 5 females) and 59 SNP sets revealed
co-segregation of the phenotype with BALB/c alleles on
chromosome 11. Further analysis, in 39 affected mice,
demonstrated co-segregation of the RCALC2 phenotype with
chromosome 11D-E2 loci (peak LOD score¼ 7.1) that spanned a
16-Mb region, flanked by D11Mit132 and D11Mit214 (Fig. 1B),
and contained over 230 genes. To identify the RCALC2 causative
gene, a whole-exome sequence analysis was performed using
DNA from two G2 RCALC2 mice, together with two control mice
consisting of one Balb/c WT mouse and one C3H WT mouse,
whichwould allow the inheritance of SNPs fromparentalmice to
be determined. This analysis identified 17 unique variants, of
which two were located on chromosome 11 (Supporting
Table 2). None of the 17 variants were in genes previously
associated with nephrocalcinosis or nephrolithiasis (Supporting
Table 1). One variant was a nonsynonymous heterozygous C-to-
A transversion at nucleotide c.795 in the Polg2 gene. The C-to-A
transversion in codon 265 of Polg2 is predicted to result in a
change of the WT amino acid residue of Tyr265 to a premature
stop codon, thereby leading to a nonsense mutation (Tyr265-
Stop, Y265X), and in a gain of a HindIII restriction endonuclease
site (A/AGCTT) (Fig. 1C). The other variant was a nonsynonymous
heterozygous change C-to-A transversion at nucleotide
c.1255 in the adenosine diphosphate (ADP)-ribosylation factor
guanosine triphosphatase (GTPase)-activating protein (ArfGAP)
with coiled-coil, ankyrin repeat, and PH domains 1 (Acap1) gene.
This variant is predicted to cause a missense amino acid change
from Gln to Lys at codon 419 (Gln419Lys, Q419K), and in a loss of
a BsrD1 restriction endonuclease site (GCAATG/NN). Bioinfor-
matic analysis using MutationTaster software(31) predicted the
Polg2 and Acap1 variants to be damaging, and studies of G2
mice using HindIII restriction endonuclease analysis (Fig. 1D)
revealed that RCALC2 co-segregatedwith the Polg2mutation, ie,
mice with renal calcification that had the Polg2mutation on the
Balb/c allele, whereas mice without calcification had the WT
(C3H) allele (n¼ 13 tested, data not shown). Further analysis of
all 85 G2 mice and 138 G3 mice revealed that 84% of G2 mice
with renal calcification, and 71% of G3 mice with renal
calcification had the Tyr265Stop Polg2 mutation (Table 1),
indicating that the mutation, which co-segregates with the
phenotype (Table 1), had a reduced penetrance. In contrast, only
50% of G2mice with renal calcification, and 50% of G3mice with
renal calcification had the Glu419Lys Acap1 mutation, showing
that the mutation does not co-segregate with the phenotype
(Table 1). Thus, the Polg2-Y265X variant co-segregates with
RCALC2, and the metabolic phenotype of mice with this
mutation was investigated in further detail.
Metabolic analysis of mice with the Polg2-Tyr265Stop
mutation
Renal calcification is often associated with metabolic abnormal-
ities including hypercalciuria, and we therefore performed
biochemical analyses of plasma and urine samples from WT
(Polg2+/+) and heterozygous mutant Polg2 (Polg2+/Y265X)
mice.(2,4,6,7) Polg2+/Y265X mice were fertile, grew at similar rates
as their Polg2+/+ littermates, had similar body weights (data not
shown), and appeared morphologically normal. Analyses of
plasma and urine samples from Polg2+/+ and Polg2+/Y265X adult
mice, aged 16 weeks, revealed no significant differences
between Polg2+/Y265X and Polg2+/+ mice in plasma concen-
trations of sodium, potassium, albumin-adjusted calcium,
chloride, urea, creatinine, glucose, phosphate, or alkaline
phosphatase activity (Table 2). Furthermore, there were no
significant differences between Polg2+/+ and Polg2+/Y265Xmice in
urine output or urinary excretion of calcium, phosphate or
oxalate which have previously been associated with renal
calcinosis(37) (Table 3). In addition, the excretion of total protein
Table 1. Analysis of Polg2 Y265X and Acap1 Q419K Variants in
RCALC2 Mice
Renal papillary calcification
Genotype Generation Present n (%) Absent n (%)
Polg2+/Y265X G2 (n¼ 43) 36 (84) 7 (16)
G3 (n¼ 72) 51 (71) 21 (29)
Polg2+/+ G2 (n¼ 42) 7 (17) 35 (83)
G3 (n¼ 66) 9 (14) 57 (86)
Acap1+/Q419K G2 (n¼ 44) 22 (50) 22 (50)
Acap1+/+ G2 (n¼ 41) 20 (49) 21 (51)
The Polg2-Y265X and Acap1-Q419K variants were investigated in the 85
G2 and 138 G3 mice. Inheritance of the Polg2 mutation co-segregated
with the RCALC2 phenotype observed in G2 and G3mice, indicating that
this is the causative mutation. In contrast, the Acap1 variant did not co-
segregate with the RCALC2 phenotype, indicating that this is not the
causative mutation for the phenotype.
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was not significantly different between the two groups, and
urinary protein analysis examined by Coomassie Blue stain,
revealed no difference between Polg2+/+ and Polg2+/Y265X mice
(Table 3; Supporting Fig. 2), suggesting that a Fanconi-like
syndrome with proteinuria is not associated with the renal
calcification. Therefore, RCALC2 is likely to represent a model of
idiopathic nephrolithiasis and nephrocalcinosis.
RCALC2 kidneys have reduced POLG2 expression
The Polg2 gene encodes the 459–amino acid POLG2 protein, and
the premature stop codon is predicted to lead to loss of the C-
terminal 194 residues that are highly conserved in the mutant
POLG2 protein (Supporting Fig. 3). Thus, the POLG2 Tyr265Stop
mutation could be predicted to result in protein reduction, due
to nonsense-mediated decay of the mutant transcript, folding
errors, and subsequent endoplasmic reticulum (ER) retention, or
a severely truncated protein. To investigate the effect of the
Tyr265Stopmutation on POLG2 cDNA expression, total RNAwas
extracted from kidneys of Polg2+/+ and Polg2+/Y265X mice, and
qRT-PCR performed using primers that bind within the first 264
amino acids of Polg2, to quantify Polg2 content (Fig. 2A). Renal
Polg2 cDNA transcript levels were significantly reduced in
Polg2+/Y265X mice compared to Polg2+/+ mice (p< 0.05, Fig. 2A).
Furthermore, analysis of renal expression of the POLG2 protein
by Western blot and densitometry analysis revealed that Polg2+/
Y265X mice had significantly reduced expression of POLG2
protein, compared to Polg2+/+ mice (Fig. 2B, Supporting Fig. 4).
In contrast, the renal expression of the DNA polymerase subunit
gamma (POLG) protein, which forms a heterotrimer with two
subunits of POLG2 to form the functionalmtDNA polymerase,(38)
was expressed at similar levels in Polg2+/+ and Polg2+/Y265X mice
(Fig. 2C, Supporting Fig. 4). Therefore, the Tyr265Stop mutation
reduces POLG2 cDNA and protein levels and this may affect
mitochondrial functions.
mtDNA levels and function
POLG2 encodes the minor subunit of the mtDNA polymerase,
which is responsible for DNA replication of 13 proteins, 22 tRNAs,
and two ribosomal RNAs (rRNAs) that are required for transcrip-
tion of mitochondria-specific proteins, including those involved
in oxidative phosphorylation.(39) Furthermore, patients with
mutations of POLG2, who have progressive external ophthalmo-
plegia (PEO), have reduced mtDNA content in their cells.(40) We
therefore hypothesized that the Polg2-Y265Xmutationmay affect
the mtDNA content in Polg2+/Y265X kidneys and compared this
with the Polg2+/+ kidneys (Fig. 3A). The copy number of mtDNA
was assessed by qRT-PCR of themitochondrially encoded NADH-
ubiquinone oxidoreductase core subunit 1 (mt-Nd1) gene and
compared to expression levels of the nuclear gene b-actin (Actb)
(Fig. 3A). The mtDNA copy number of Polg2+/Y265X mice was
significantly reduced compared to Polg2+/+ mice (Fig. 3A).
Because the mtDNA content of Polg2+/Y265Xmice was reduced,
we hypothesized that other genes involved in mitochondrial
function may also be affected by the Polg2+/Y265X mutation. We
therefore assessed expression of all genes in kidneys from Polg2+/
Y265X and parental Balb/c and C3H mice by cDNA expression
Table 3. Urine Biochemical Studies of Polg2+/Y265X (Mutant) and Polg2+/+ (WT) Mice
Male Female
Polg2+/+ (n¼ 19) Polg2+/Y265X (n¼ 17) Polg2+/+ (n¼ 11) Polg2+/Y265X (n¼ 14)
Urine output (mL/24 hours) 2.20 0.65 2.14 0.45 1.43 0.46 1.55 0.40
Fractional excretion calcium 0.003 0.001 0.004 0.002 0.005 0.002 0.005 0.003
Fractional excretion phosphate 0.14 0.72 0.17 0.25 0.11 0.04 0.11 0.07
Oxalate/creatinine 0.22 0.01 0.29 0.10 0.19 0.03 0.19 0.05
Protein (mg/dL) 982.86 406.74 960.59 218.19 465.25 146.75 401.04 87.49
Values are expressed as mean SD. Urine biochemical analysis was performed on adult (16-week-old) WT (Polg2+/+) and RCALC2 (Polg2+/Y265X) mice, in
metabolic cages, using urine samples collected over a 24-hour period.
WT¼wild-type.
Table 2. Plasma Biochemical Studies of Polg2+/Y265X (Mutant) and Polg2+/+ (WT) Mice
Male Female
Polg2+/+ (n¼ 19) Polg2+/Y265X (n¼ 17) Polg2+/+ (n¼ 11) Polg2+/Y265X (n¼ 14)
Sodium (mmol/L) 154.32 2.40 154.71 2.54 151.36 1.21 151.21 1.67
Potassium (mmol/L) 6.15 0.59 6.55 0.83 6.15 0.84 6.08 0.78
Calcium (mmol/L)a 2.32 0.07 2.31 0.05 2.38 0.10 2.34 0.09
Chloride (mmol/L) 115.05 1.72 116.18 2.46 114.73 1.19 115.43 1.87
Urea (mmol/L) 8.89 1.70 8.25 1.33 7.39 1.03 6.85 0.90
Creatinine (mmol/L) 33.79 5.44 33.57 4.26 37.36 4.41 33.57 5.12
Glucose (mmol/L) 9.65 3.59 9.70 2.45 10.89 1.04 10.05 0.97
Phosphate (mmol/L) 2.77 1.00 2.77 1.00 2.08 0.44 2.20 0.43
ALP (U/L) 48.24 5.71 48.24 5.71 78.00 18.53 87.64 19.43
All values are expressed as mean SD. Plasma biochemical analysis was performed on adult (16-week-old) WT (Polg2+/+) and RCALC2 (Polg2+/Y265X)
mice.
WT¼wild-type; ALP¼ alkaline phosphatase activity.
aPlasma calcium concentrations were adjusted for the plasma albumin concentration.
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profiling. This revealed 26 genes to be differentially expressed
(p< 0.05, fold change >1.10) between Polg2+/Y265X and parental
Balb/c and C3H mice (Polg2+/+) (Supporting Table 3). Of these 26
genes, 13 genes were significantly upregulated and 13 genes
were significantly downregulated in Polg2+/Y265X kidneys
compared to parental Balb/c and C3H kidneys (Supporting
Table 3). Further analyses revealed that these genes fell into eight
broad categories of biological function including genes involved
in: mtDNA function (n¼ 5), in which POLG2 is known to be
essential; complement pathway components (n¼ 3); inflamma-
tory pathways (n¼ 4); and apoptosis and ubiquitination (n¼ 4),
which may be activated by damaged mitochondria.(37) Changes
in gene transcription were validated by qRT-PCR analysis in
kidney cDNA samples from four Polg2+/+ and four Polg2+/Y265X
mice (Fig. 3B–H, Supporting Table 4). Thus, the differential
expression of one upregulated gene (ubiquitin-conjugating
enzyme E2 [Ube2c]) involved in ubiquitination (Fig. 3B); two
upregulated genes (complement component 1, q subcompo-
nent, C chain [c1qc] and complement component 3 [c3]) that
encode components of the complement pathway (Fig. 3C,D); one
upregulated (apolipoprotein M [Apom]) and one downregulated
gene (peroxisomal membrane protein 4 [Pxmp4]) involved in
inflammatory pathways (Fig. 3E, F); and one upregulated
(mitochondrial ribosomal protein L3 [Mrpl3]) and one down-
regulatedgene (glycerol phosphate dehydrogenase 2,mitochon-
drial [Gpd2]) that are involved in mtDNA function (Fig. 3G, H) in
Polg2+/Y265X kidneys, were confirmed by qRT-PCR analysis. These
findings indicate that the Polg2-Y265X mutation affects the
expression of genes involved in multiple cellular mechanisms.
Because the cDNA expression profiling analysis and qRT-PCR
validation revealed changes in genes encoding proteins
important for mtDNA function (Fig. 3, Supporting Table 3), we
hypothesized that the POLG2-Tyr265Stop mutation may impair
mitochondrial processes such as oxidative phosphorylation and
apoptosis. Disruption of oxidative phosphorylation has previ-
ously been shown to lead to increases in ROSwithin cells, rodent
models, and in patients with nephrolithiasis, and these increases
in ROS have been hypothesized to contribute to renal cell
damage, and consequently crystal retention and nephrocalci-
nosis.(37,41–43) To determine if the POLG2-Tyr265Stop mutation
increased ROS production, we assessed levels of ROS(36) in
plasma samples from Polg2+/+ and Polg2+/Y265Xmice. Plasma ROS
levels were significantly higher in mutant POLG2 Tyr265Stop
mice (mutant¼ 1.86 0.20 versus WT¼ 1.00 0.10, p< 0.02)
(Fig. 4A), indicating that the Polg2 mutation may increase
mitochondrial damage and consequently ROS production. We
hypothesized that this increase in ROS production may be
associated with changes in the expression of genes involved in
oxidative phosphorylation in Polg2+/Y265X mice compared to
Fig. 2. Continued.
Fig. 2 Effect of the Polg2+/Y265X mutation on cDNA and protein
expression. (A) Renal expression of Polg2 was assessed in Polg2+/+ and
Polg2+/Y265X mice using qRT-PCR (n¼ 4 to 5 mice for each). All data was
normalized to the geometric mean of three housekeeper genes, Ccnd1,
Ccnd2, and Actb, and expressed as a fold-change relative to that in
Polg2+/+ mice. DCT values are included in Supporting Table 4. (B, C)
Western blot analysis of (B) POLG2 and (C) POLG and the housekeeper
gene calnexin, which was used as a loading control, in whole-kidney
lysates of 4 Polg2+/+ and 4 Polg2+/Y265X mice using an antibody
targeting the N-terminal region of Polg2. Smaller products were not
observed for POLG2, indicating that a truncated protein is not present
in the mouse kidneys. (Bottom) Densitometric analysis of POLG2 and
POLG from Western blot analyses. Histograms are presented as
mean SE. Statistical analyses using Student’s t test, comparing
Polg2+/+ and Polg2+/Y265X mice for A, C, and D. p< 0.05. Full Western
blots are shown in Supporting Fig. 4.
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Polg2+/+ mice. Therefore, the cDNA transcript levels of two
genes, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex
subunit 1 (Ndufa1) and Cytochrome C oxidase subunit NDUFA 4
(Ndufa4), which encode components of the mitochondrial
oxidative phosphorylation complex I and complex IV, respec-
tively,(44,45) were assessed in renal cDNA samples from Polg2+/+
and Polg2+/Y265X mice by qRT-PCR analysis. This revealed
reduced expression of the Ndufa1 transcript in Polg2+/Y265X
kidneys compared to Polg2+/+ mice, whereas Ndufa4 transcript
levels were similar (Fig. 4B, Supporting Table 4). Furthermore,
assessment of the acyl-CoA dehydrogenase medium chain
(Acadm) gene that catalyses the first step of the mitochondrial
b-oxidation pathway, impairments of which have been shown
to activate oxidative stress,(46) were not significantly
different between the Polg2+/+ and Polg2+/Y265X mice (Fig. 4C,
Supporting Table 4). This indicates that the changes in ROS
may be associated with changes in the expression of complex
I components, but are not associated with changes in the
b-oxidation pathway.
We next assessed the effect of the POLG2-Tyr265Stop
mutation on apoptosis as mitochondria play a critical role in
this process,(42) and genes involved in apoptosis are differen-
tially expressed in the kidneys of Polg2+/Y265X mice (Supporting
Table 3). The apoptotic genes identified in the cDNA expression
profiling to be differentially expressed do not encode the critical
components of mitochondrial apoptotic pathways. We there-
fore assessed the expression of apoptotic genes known to
directly act within the mitochondrial apoptosis pathway. This
demonstrated that Cycs, which encodes cytochrome C that
mitochondria release when triggered by apoptosis,(47) was
expressed at significantly higher levels in kidneys from Polg2+/
Y265Xmice compared to Polg2+/+ (Fig. 4D). Despite this, there was
no significant difference in cDNA expression levels of two
enzymes, caspase 3 (Casp3) and caspase 9 (Casp9), that form part
of the cascade that is activated directly by cytochrome C(47)
(Fig. 4D, Supporting Table 4). Measurement of active caspase 3/7
using the CaspaseGlo chemiluminescent assay and kidneys from
Polg2+/+ and Polg2+/Y265X mice revealed no difference in
apoptosis between the two groups consistent with previous
findings in Polg2 heterozygous (Polg2+/–) knockout mice(48)
(Fig. 4E, Supporting Table 4). Finally, we examined whether
genes encoding proteins in the phagocytosis pathway, which
requires changes in mitochondrial membrane potential for
engulfment to occur efficiently, were differentially expressed in
the kidneys of Polg2+/Y265X mice. We assessed the expression of
uncoupling protein 2 (Ucp2), which regulates mitochondrial
membrane potential and is upregulated in phagocytes engulf-
ing apoptotic cells, and T cell immunoglobulin and mucin
domain containing 4 (Timd4), an engulfment receptor that
recognizes apoptotic cells.(49,50) Renal Ucp2 cDNA transcript
levels were significantly increased, while Timd4 was similarly
expressed in Polg2+/Y265Xmice, when compared to Polg2+/+mice
(Fig. 4F, Supporting Table 4). Thus, the Polg2+/Y265X mutation
likely has a selective effect on mitochondrial functions.
Discussion
Our studies have demonstrated that renal calcification in a
mutant mouse model is due to a heterozygous germline
Tyr265Stop mutation of Polg2, which encodes the POLG2
protein that forms part of a heterotrimeric complex composed
of two POLG2 subunits and one catalytic POLG subunit.(39)
Mutations in both POLG and POLG2 cause diseases in humans,
Fig. 3. Assessment of gene expression by qRT-PCR analysis. (A) ThemtDNA content of kidneys from Polg2+/+ and Polg2+/Y265Xmice was assessed by qRT-
PCR analysis usingmt-Nd1 as a representative gene ofmtDNA, and Actb as a nuclear housekeeper gene. Data is expressed as the ratio ofmt-Nd1 and Actb.
n¼ 4 mice for each group. Statistical analyses were performed by Student’s t test comparing Polg2+/+ and Polg2+/Y265X mice, p< 0.05. The levels of
mtDNA in Polg2+/Y265X mice were significantly reduced, compared to Polg2+/+ mice. (B–H) Validation of differentially expressed genes from cDNA
microarray analysis of kidney lysates from Polg2+/+ and Polg2+/Y265Xmice by qRT-PCR analysis. Renal expression of: (B) Ube2c, (C) c1qc, (D) c3, (E) Apom, (F)
Pxmp4, (G)Mrpl3, and (H) Gpd2 genes, in cDNA from Polg2+/+ and Polg2+/Y265Xmice. n¼ 4 to 5mice for each group.DCT values are included in Supporting
Table 4. Histograms are presented as mean SE. Statistical analyses were performed by Student’s t test, p< 0.05, p< 0.02.
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referred to as the POLG-related disorders, which have awide and
not well-defined spectrum of overlapping phenotypes.(51) These
POLG-related disorders include: childhood myocerebrohepat-
opathy spectrum (MCHS), characterized by developmental
delay, lactic acidosis, myopathy, failure to thrive, and sometimes
liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting,
and hearing loss(51); Alpers-Huttenlocher syndrome, character-
ized by encephalopathy, intractable seizures, neuropathy, and
liver failure(52); myoclonic epilepsy myopathic sensory ataxia
(MEMSA); ataxia neuropathy spectrum (ANS); autosomal
recessive progressive external ophthalmoplegia (ArPEO); and
autosomal dominant progressive external ophthalmoplegia
(AdPEO). POLG mutations cause the autosomal recessive
diseases MCHS, Alpers-Huttenlocher syndrome, MEMSA, ANS,
and ArPEO, as well as AdPEO; whereas POLG2 mutations, which
are usually heterozygous, cause AdPEO, as well as dysfunctions
Fig. 4. Assessment of mitochondrial function and apoptosis in Polg2+/Y265X mice. (A) ROS production in plasma samples from Polg2+/+ and Polg2+/Y265X
mice. ROS production was significantly higher in plasma from Polg2+/Y265Xmice compared to Polg2+/+mice. Data is expressed as a fold change compared
to Polg2+/+ WT mice. n¼ 4 mice for each group. (B, C) Assessment of cDNA transcript levels of the Ndufa1 and Ndufa4 genes, which are involved in (B)
oxidative phosphorylation, and (C) the Acadm gene, which is involved in b-oxidation, in cDNA from Polg2+/+ and Polg2+/Y265X mice by qRT-PCR analysis.
n¼ 4 mice for each group. (D) Assessment of cDNA transcript levels of the Cycs, Casp3, and Casp9 genes, which are involved in apoptosis, in cDNA from
Polg2+/+ and Polg2+/Y265X mice by qRT-PCR analysis. n¼ 4 mice for each group. (E) Induction of active caspase 3/7 in kidneys from Polg2+/+ and Polg2+/
Y265Xmice measured by the CaspaseGlo luminescence assay. n¼ 10mice for each group. No significant difference was seen between the two groups. (F)
Assessment of cDNA transcript levels of the Ucp2 and Timd4 genes, which are involved in phagocytosis in cDNA from Polg2+/+ and Polg2+/Y265X mice by
qRT-PCR analysis. n¼ 4 mice for each group. DCT values are included in Supporting Table 4. Histograms are presented as mean SE for all panels.
Statistical analyses were performed by Student’s t test. p< 0.05, p< 0.01, and p< 0.001. ROS¼ reactive oxygen species.
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of the central and/or neuromuscular systems.(40) Renal tubular
disease has been reported only occasionally in MCHS patients
with POLG mutations, but not in those with POLG2 muta-
tions.(51,53) However, assessments for renal calcification may not
have been undertaken in these patients with POLG2 mutations,
and it is important to note that individuals heterozygous for
POLG2 or POLG mutations have also been reported as having a
normal phenotype. Moreover, the majority of POLG2 mutations
reported to date in humans are missense mutations(54) that may
act differently to the nonsense Polg2+/Y265X mutation, reported
in this study of mutant RCALC2 mice. In addition, ocular defects
were not observed in the Polg2+/Y265Xmice, and this is consistent
with reports of previous mouse models in which heterozygous
Polg and Polg2 knockout mice developed normally and had no
phenotypes associated with mitochondrial disease.(48,55) This is
in contrast to mice with homozygous deletion of Polg and Polg2,
which are lethal in early development and by embryonic days
7.5 to 8.5.(48,55) These studies therefore indicate that the
heterozygous deletions of the POLG2 knockout mice and
nonsensemutations of the Polg2+/Y265Xmice likely act differently
to the mutations observed in man, which act in a dominant-
negative manner.(54) Because our studies showed a reduction in
POLG2 protein in the Polg2+/Y265X mice (Fig. 2), indicating likely
degradation of the mutant product, we did not breed
homozygous Polg2Y265X/Y265X mice, because these would likely
be embryonically lethal and therefore not provide further
information about the renal phenotype.
The Polg2+/Y265X mice have calcification predominantly of the
renal papilla and cortex (Fig. 1), which is consistent with the
hypothesis that calcification typically occurs late in the renal
tubular pathway, following precipitation of calcium crys-
tals.(56,57) This precipitation is often associated with a metabolic
defect such as hypercalciuria; inflammation or damage to
epithelial layers by aberrant signaling or ROS; or changes in gene
expression (eg, stone inhibitors).(2,4,6,7,43)Our studies did not find
the Polg2+/Y265X mice to have any metabolic defects (Tables 2
and 3) or tissue damage such as apoptosis and fibrosis (Fig. 4,
Supporting Fig. 1), but did find aberrant signaling, a rise in ROS
and changes in gene expression to be present in the kidneys of
the Polg2+/Y265X mice (Figs., 3, and 4 2). Thus, the Polg2-
Tyr265Stop mutation was associated with reduced levels of
POLG2 (Fig. 2), decreased levels of mtDNA (Fig. 3), changes in
expression of genes encoding components of mitochondrial
specific processes (including mitochondrial ribosomal proteins
[Mrpl3], components of the electron transport chain and
oxidative phosphorylation complex I [Gpd2 and Ndufa1], and
phagocytosis [Ucp2] [Figs. 3 and 4]), and an increase in
production of ROS (Fig. 4). Therefore, we propose the following
model for nephrocalcinosis in the RCALC2 model. In cells of
animals with the Polg2+/Y265Xmutation some interaction will still
occur between the WT POLG2 and POLG protein, but this may
not be as efficient as the mutant POLG2 is unlikely to be
transcribed, which results in reduced total mtDNA. Genes
involved in mitochondrial-specific processes such as Gpd2 and
several mitochondrial ribosomal proteins, which encode essen-
tial enzymes and proteins involved in protein synthesis within
the mitochondrion are differentially expressed (Supporting
Table 3, Fig. 3). These changes may contribute to the increased
ROS observed in plasma samples from Polg2+/Y265X mice (Fig. 4),
which may cause injury to cells allowing sites for crystal
retention to develop.(43) These changes could then include
inflammation, as evidenced by differential expression of genes
involved in: inflammation (eg, Apom, alanyl aminopeptidase
[Anpep], Apolipoprotein C-I [ApocI], and Pmxp4); and the
complement component pathway (eg, C1qb, C1qc, and C3)
(Supporting Table 3, Supporting Fig. 3). In conclusion, the
RCALC2mouse, which is associated with a nonsensemutation in
POLG2 represents a model of idiopathic renal calcification and
provides an in vivo resource for further mechanistic studies of
abnormalities of renal calcium deposition.
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